A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib. (2021)

• Record Type: Journal Article
• Authors: Inoue, Yukihisa; Matsubara, Osamu; Ohira, Yumi; Endo, Satoshi; Jinn, Yasuto
• Is Part Of: Respiratory medicine case reports. Volume 33(2021)
• Publication Date: 2021
• Subjects: Osimertinib -- Alectinib -- EGFR mutation -- ALK rearrangement -- Synchronous multiple primary lung cancers; SMPLC synchronous multiple primary lung cancers -- EGFR epidermal growth factor receptor -- ALK anaplastic lymphoma kinase -- NSCLC non-small cell lung cancer -- CT computed tomography -- GGN ground glass nodule -- LLL left lower lobe -- RLL right lower lobe -- LUL left upper lobe -- RUL right upper lobe -- CEA carcinoembryonic antigen; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2021.101418
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Synchronous multiple primary lung cancers (SMPLC) should be distinguished from intrapulmonary metastasis to define the optimal treatment approach. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are typically mutually exclusive and the co-existence of both mutations is relatively rare. Herein, we report a case of SMPLC harboring each EGFR mutation and ALK rearrangement successfully treated with combination of osimertinib and alectinib. A combination of EGFR- and ALK-tyrosine kinase inhibitors could be an effective and tolerable therapeutic option for SMPLC with EGFR mutations and ALK rearrangement.